Non-invasive diabetes device developer Sensys relocates to UK

NOVEMBER 21, 2008 -- Sensys Medical (Chandler, AZ), developer of non-invasive blood glucose monitoring technology, is relocating its world headquarters to the UK according to UK Trade and Investment. Sensys's device is able to read blood glucose levels an unlimited number of times a day via near-infrared spectrometry, and is expected to greatly enhance diabetes management.

According to Robert Curry, CEO of Sensys Medical, "Moving to the UK is an exciting step for us as a business focused on the global diabetes epidemic. We believe that the UK represents the best hub to build a world-class medical device company. It provides us with crucial access to markets such as China, where it's estimated that during the 21st century almost a million new cases of diabetes will occur each year. "Our plan is to be well established commercially in Europe, the US and the Middle East over the next few years, and from that base to launch into India and China." Sensys Medical Ltd (Sensys UK), anticipates hiring 20-30 individuals from within the UK over the coming months.

The company was aided by UK Trade and Investment's Global Entrepreneur Programme (GEP) in making the move. Clinical trials of the technology are due to begin towards the end of 2009, with CE mark approval due by April of 2010.

To accelerate the adoption of its technology, Sensys UK has initiated a review with Great Britain's National Health Service (NHS) Technology Adoption Centre with the help of UK Trade and Investment. The process will yield a roadmap for commercializing the technology, which is expected to drive cost savings for the NHS. Sensys has also met with the UK Diabetes Research Network Coordinating Centre based at Imperial College in London, which will provide a clinical trial site as part of the company's pivotal clinical trial for regulatory approval by both the CE authorities and the US Food and Drug Administration.

More information:
UK Trade and Investment

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

Piezo stage for super-resolution microscopy by PI

The PInano II high-resolution XY/XYZ multi-axis positioning stages include a piezo scanner, software, and digital servo piezo controller.

Noninvasive transcranial NIR light therapy has potential to treat PTSD

Findings on the effects of transcranial NIR light therapy could result in an noninvasive treatment for brain disorders like PTSD.

Third FDA-approved study supports additional potential use of laser ablation technology

The FDA has approved an additional Investigational Device Exemption (IDE) to evaluate the NeuroBlate laser ablation system.

Cell Biology/Cardiology: Ultra-stable micromanipulators enable nanoscale force measurement

Leading-edge heart disease research requires the capabilities of next-generation optical instrumentation. Behind the scenes, three-axis micromanipulators let researchers pick up single cells and pe...


Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...



Twitter- BioOptics World

Copyright © 2007-2016. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS